Vol.6 Neurodevelopmental Liabilities in Brain Disease States

TABLE OF CONTENTS

I.Schizophrenia an Affective Disorders

1. Control of the Serotonergic System by the Medial Prefrontal Cortex: Potential Role in the Etiology of PTSD and Depressive Disorders. Pau Celada, M. Victoria Puig, Raúl Martín-Ruiz, et al.
2. Neonatal Exposure to the Glutamate Receptor Antagonist MK-801: Effects on Locomotor Activity and Pre-pulse Inhibition Before and After Sexual Maturity in Rats. R.J. Beninger, A. Jhamandas, H. Aujla, et al.
3. Neurovulnerability to Immune System Alterations During Development. José Borrell, José Miguel Vela, Angel Arévalo-MartÍn, Eduardo Molina-Holgado and Carmen Guaza
4. Neuropeptides Involved in the Pathophysiology of Schizophrenia and Major Depression. David de Wied, Hein O. Sigling.
5. In Memoriam Béla Bohus 1936-2000. David de Wied
6. Neurodevelopmental Influences on the Immune System Reflecting Brain Pathology. Rolf Ekman, Rita Persson, Carol L. Nilsson.
7. Human Genetic Variation and Mental Disorders. Bárbara Arias, Araceli Rosa, Lourdes Fañanás.
8. Developmental Markers of Psychiatric Disorders as Identified by Sensorimotor Gating. Susan B. Powell, Mark A. Geyer.
9. Memory Retrieval and its Lasting Consequences. Iván Izquierdo, Mónica R.M. Vianna, Luciana A. Izquierdo, et al.
10. A Neurodevelopmental Model of Schizophrenia: Neonatal Disconnection of the Hippocampus. Barbara K. Lipska, Daniel R. Weinberger.
11. Multimodal Neuroimaging Studies and Neurodevelopment and Neurodegeneration Hypotheses of Schizophrenia. Vicente Molina, Santiago Reig,Manuel Desco, et al.
12. Schizophrenia and Bipolar Disorder are Distinguished Mainly by Differences in Neurodevelopment. Jenny Walker, Vivienne Curtis, Philip Shaw, et al.
13. Crossroads of Corticotropin Releasing Hormone, Corticosteroids and Monoamines. H.M. van Praag.
14. Regulation of the Hypothalamic-pituitary-adrenal Axis in the Neonatal Rat: The Role of Maternal Behavior. Seymour Levine.
15. Risk Factors for the Neurohumoral Alterations Underlying Personality Disturbances. Lars Oreland, Mattias Damberg, Jarmila Hallman, et al.
16. Neurodevelopmental Liabilities in Schizophrenia and Affective Disorders. Tomás Palomo, Richard M. Kostrzewa, Trevor Archer, et al.
17. Estrogen and Brain Vulnerability. Iñigo Azcoitia, Lydia L. Doncarlos, Luis M. Garcia-Segura.

II. Substance Abuse

18. Mechanisms Involved in Central Nervous System Dysfunctions Induced by Prenatal Ethanol Exposure. Consuelo Guerri.
19. Individual Vulnerability to Substance Abuse and Affective Disorders: Role of Early Environmental Influences. Muriel Koehl, Valérie Lemaire, Willy Mayo, et al.
20. Neuroadaptations to Chronic Exposure to Drugs of Abuse: Relevance to Depressive Symptomatology Seen Across Psychiatric Diagnostic Categories. Athina Markou, Paul J. Kenny.
21. Glutamate and GABA Receptor Dysfunction in the Fetal Alcohol Syndrome. John W. Olney, David F. Wozniak, Vesna Jevtovic-Todorovic.
22. Exposure to Cannabinoids in the Development of Endogenous Cannabinoid System. José A. Ramos, Rosario de Miguel, Maribel Cebeira, et al.
23. Deviations in Brain Early Serotonergic Development as a Result of Fetal Alcohol Exposure. Feng C. Zhou, Youssef Sari, Ting-Kai Li, et al.
24. Neurodevelopmental Liabilities in Alcohol Dependence: Central Serotonin and Dopamine Dysfunction. Claudio A. Naranjo, Alan Y. Chu, Lescia K. Tremblay.
25. The Neurobiology of Opiate Tolerance, Dependence and Sensitization: Mechanisms of NMDA Receptor-dependent Synaptic Plasticity. Keith A. Trujillo.
26. Neurodevelopmental Liabilities of Substance Abuse. Tomas Palomo, Trevor Archer, Richard J. Beninger, et al.
27. Postnatal iron Exposure-Induced Neurofunctional Deficits: Esperimental Parkinsom. Trevor Archer.

III.Movement Disorders

28. Parkinson’s Disease Pathology: Role of a Synuclein in Normal and Disease States. M. Catherine Bennett, Yan Leng, Gerda Andringa, Xiaoxia Wang and Thomas N. Chase.
29. Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Thomas N. Chase, Francesco Bibbiani and Justin D. Oh.
30. Neurotrophic factors for the investigation and treatment of Movement Disorders. Justo García de Yébenes, Marina Sánchez, María Angeles Mena.
31. Fluoxetine Response in YoungChildren with Autistic Spectrum Disorders: Correlaction with Familial Major Affective Disorder and Unusual Intellectual Achivementt. G. Robert DeLong, Chad R. Ritch, Sherri Burch.
32. The Potential Role of Neuromelanin and its Interaction with Iron in the Dopaminergic Neurodegeneration Underlying Parkinson´s Disease. Manfred Gerlach, Kay L. Double, Dorit Ben-Shachar, Luigi Zecca, Moussa B.H. Youdim, and Peter Riederer.
33. The Destructive Propensities of Perinatal Neurotoxins on Brain Development and Fuction. Richard M. Kostrzewa.
34. Neurodevel Opmental Liabilities in Epilepsy. Antonio Gil-Nagel.
35. Developmental factors Leading to Movement Disorders. Peter Riederer.
36. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: implications for neurodevelopmental Psychiatric disorders. Pierre Sokoloff, Olivier Guillin, Jorge Diaz, Patrick Carroll, Nathalie Griffon, and Jean-Charles Schwartz.
37. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Carl Bjartmar and Bruce D. Trapp.
38. A Possible Physiological Role for Cerebral Tethrahydroisoquinolines. Jerzy Vetulani.
39. Molecular Events in Neurodegeneration and Neuroprotection in Parkinson´s Disease and its MPTP Animalmodel as Asessed by CDNA Microarray. Silvia Mandel , Edna Grünblatt , Yona Levites , Gila Maor and Moussa B.H.Youdim Peter Riederer.

Fundación Cerebro y Mente

c/ General Oraa, 47 - 1º E

28006 Madrid, España

Telf: +34 91 561 1267

Fax: +34 91 564 1817